Executive Intelligence

Eva van Rikxoort

Founder

Eva van Rikxoort is listed as a founder of Thirona based in Netherlands on Brel Digital’s verified company intelligence record.

Company Intelligence Official Website
In this profile

Quick Facts

  • Role Founder
  • Company Thirona
  • Country Netherlands
  • Industry AI in Healthcare
  • Founded 2014
  • Known For Thirona's LungQ 4 FDA clearance extends peripheral airway segmentation and perfusion estimation into U.S. interventional pulmonology…
  • Status Active
  • Last Reviewed Jul 2026

Executive Summary

Eva van Rikxoort appears in Brel Digital’s verified company_founders attribution for Thirona based in Netherlands in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified Thirona profile): Nijmegen thoracic CT AI company advancing LungQ pulmonary segmentation and intervention planning with serial FDA clearances Why the company matters (verified company field): Thirona's LungQ 4 FDA clearance extends peripheral airway segmentation and perfusion estimation into U.S. interventional pulmonology workflows — Eva van Rikxoort's serial 510(k) strategy shows lung AI maturing from research segmentation into reimbursable clinical tools. Official company website on file: https://thirona.eu. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2014 Company founded

    Thirona was founded in 2014 per the company profile source on file.

    Source
  2. 2014 Development

    2014: Thirona founded in Nijmegen by Eva van Rikxoort, PhD.

    Source
  3. 2024 Development

    January 22, 2024: LungQ 3.0.0 FDA 510(k) clearance announced.

    Source
  4. 2025 Development

    2025: LungQ 4 FDA 510(k) clearance for enhanced airway segmentation, PXT perfusion, and implant detection (official source).

    Source

Connected Company

Connected Products

Connected Reports

Connected Insights

Industry Intelligence

AI in Healthcare Open industry

Eva van Rikxoort appears in Brel Digital’s verified company_founders attribution for Thirona based in Netherlands in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified Thirona profile): Nijmegen thoracic CT AI company advancing LungQ pulmonary segmentation and intervention planning with serial FDA clearances

Why the company matters (verified company field): Thirona's LungQ 4 FDA clearance extends peripheral airway segmentation and perfusion estimation into U.S. interventional pulmonology workflows — Eva van Rikxoort's serial 510(k) strategy shows lung AI maturing from research segmentation into reimbursable clinical tools.

Official company website on file: https://thirona.eu. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Request a correction if you represent this company or believe information is inaccurate.

The AI Brief

Founder and company intelligence, weekly.

Subscribe